Bypassing the Petri Dish: How 3D Bioprinting and Organ-on-a-Chip Models Are Redefining Drug Testing

The scientific pursuit of human health has long relied on animal models, a standard that, while foundational, is increasingly proving inadequate. Charu Chandrasekera, through her work with the Canadian Centre for Alternatives to Animal Methods, has spearheaded the transition toward sophisticated in vitro systems. Her vision is not merely to replace animal tests one-for-one, but to advance biomedical research using the most physiologically accurate tools available. This approach centers on creating complex, living systems—such as bioprinted human liver tissue or heart models—that mimic human function with high fidelity.

Chandrasekera’s scientific credentials, including her work utilizing 3D bioprinting and in silico modeling, underline a deep grasp of both biochemistry and molecular biology. Her position as an internationally recognized voice in regulatory science—representing Canada on the ICATM consortium and advising US/EU bodies—is critical. She is establishing a global framework, advocating for the acceptance of these complex methods by regulatory bodies like Health Canada. The core argument is compelling: these alternative models offer a pathway to better predictive accuracy, bypassing the notorious rate at which animal-tested drugs fail in human clinical trials.

While Canada is structurally prepared with key legislation (like Bill S-5 for toxicology), the lack of sustained funding for biomedical alternative testing, as highlighted by the temporary closure of her lab, represents a critical national gap. This stalls the development of a necessary $30 billion industry and jeopardizes Canada’s standing as a leader in translational science.